Presentations & Publications An open-label, active-controlled phase 2 evaluation of novel GLP-1 analog ecnoglutide (XW003) in adults with obesityADA 2023 A phase 1c evaluation of a novel GLP-1 analog ecnoglutide (XW003) for weight loss in adults with overweight & obesityADA 2023 A phase 2 evaluation of a novel GLP-1 analog ecnoglutide (XW003) for glycemic control in adults with type 2 diabetesADA 2023 Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014EASL 2022 Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse modelEASL 2022
